Fig. 3From: Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trialKaplan-Meier estimates of radiological progression-free survival and overall survival. A Radiological progression-free survival. B Overall survivalBack to article page